Bay 59-3074

SKU: orb1225100

Description

A potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively; displays antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic; orally acitve.

Key Properties

• CAS Number: 406205-74-1
• MW: 453.3555
• Purity: >98% (HPLC)
• Formula: C₁₈H₁₃F₆NO₄S
• SMILES: O=S(CCCC(F)(F)F)(OC1=CC=CC(OC2=CC=CC(C(F)(F)F)=C2C#N)=C1)=O
• Target: Cannabinoid Receptor
• Solubility: DMSO: ≥ 34 mg/mL

Bioactivity

• In Vivo:
  BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain. Animal model: Male Wistar rats (160-250 g). Dosage: 0.3 mg/kg, 1 mg/kg, and 3 mg/kg. Administration: Oral administration; daily; for 2 weeks. Result: Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bay59-3074 | Bay-59-3074

Quick Database Links

Gene Symbol

Cannabinoid Receptor